China boost for AstraZeneca lung cancer treatment
AstraZeneca has received a significant authorisation in China for a lung cancer treatment.
China’s National Medical Products Administration has approved Tagrisso (osimertinib) as a first-line treatment for adults with locally-advanced or metastatic non-small cell lung cancer following successful trials.
Dave Fredrickson, AstraZeneca’s executive VP for oncology, said: “The FLAURA trial has demonstrated the potential of Tagrisso as a new standard of care and as an important new first-line treatment option for non-small cell lung cancer patients in China, where approximately 30-40 per cent are diagnosed with an EGFR mutation – more than any other country in the world.”
AstraZeneca recently announced that Tagrisso additionally showed a statistically-significant and clinically-meaningful improvement in overall survival in the patient population tested in the FLAURA trial.
Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-fifth of all cancer deaths – more than breast, prostate and colorectal cancers combined.